WO2004040298A3 - Tumor marker proteins for diagnosis and therapy of cancer and cancer risk assessment - Google Patents

Tumor marker proteins for diagnosis and therapy of cancer and cancer risk assessment Download PDF

Info

Publication number
WO2004040298A3
WO2004040298A3 PCT/EP2003/012162 EP0312162W WO2004040298A3 WO 2004040298 A3 WO2004040298 A3 WO 2004040298A3 EP 0312162 W EP0312162 W EP 0312162W WO 2004040298 A3 WO2004040298 A3 WO 2004040298A3
Authority
WO
WIPO (PCT)
Prior art keywords
ncbi
binding protein
precursor
cancer
light chain
Prior art date
Application number
PCT/EP2003/012162
Other languages
French (fr)
Other versions
WO2004040298A2 (en
Inventor
Volker Seibert
Stephanie Lamer
Kirsten Rothmann-Cosic
Silvia Tortola Perez
Tatiana Ilyina
Steffen Heim
Joern Meuer
Thomas Buschmann
Marie-Laure Fogeron
Der Linden Mark Van
Original Assignee
Europroteome Ag
Volker Seibert
Stephanie Lamer
Kirsten Rothmann-Cosic
Silvia Tortola Perez
Tatiana Ilyina
Steffen Heim
Joern Meuer
Thomas Buschmann
Marie-Laure Fogeron
Der Linden Mark Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Europroteome Ag, Volker Seibert, Stephanie Lamer, Kirsten Rothmann-Cosic, Silvia Tortola Perez, Tatiana Ilyina, Steffen Heim, Joern Meuer, Thomas Buschmann, Marie-Laure Fogeron, Der Linden Mark Van filed Critical Europroteome Ag
Priority to AU2003282069A priority Critical patent/AU2003282069A1/en
Publication of WO2004040298A2 publication Critical patent/WO2004040298A2/en
Publication of WO2004040298A3 publication Critical patent/WO2004040298A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to agents and methods for the diagnosis and therapy of cancer and further to the identification of cancer associated marker. The following tumor marker were identified: S-100type calcium binding protein A14 (BC005019) NCBI 10190712, unknown(BC007716)/GTP-specific succinyl-CoA synthetase beta subunit (AF058954) NCBI 14043451, ATP Synthase D Chain O75947, Cathepsin E Precursor P07339, Cathepsin E Precursor/Gastricin precursor (Pepsonogen C) P14091, Complement Component 1, Q Subcomponent Binding Protein Q07021, Dihydrolipoamide Dehydrogenase, mitochondrial precursor P09622, Electron Transfer Flavoprotein-Ubiquinone Oxidoreductase Q16134, Fumarate Hydratase, mitochondrial precursor P07954, IgG Fc binding protein NCBI 4321127, Myosin Light Chain Alkali, non muscle isoform/Myosin Light Chain Alkali, smooth-muscle P16475/P24572, Myosin regulatory light chain 2, smooth muscle isoform/Myosin regulatory light chain 2, nonsarcomeric P19105/P24844, NADH-Ubiquinone Oxidoreductase 42 kda Subunit O95299, PDZ and LIM Domain Protein 1 O00151, Poly(RC)-Binding Protein 1 Q15365, NCBI 4506237, Proteasome activator hPA28 subunit beta Q15365, NCBI 4506237, S 100 calcium-binding protein A14/Calgizzarin (91% identity) O60417/P31949 and/or Succinate Dehydrogenase [ubiquinone] Flavoprotein P31040.
PCT/EP2003/012162 2002-11-01 2003-10-31 Tumor marker proteins for diagnosis and therapy of cancer and cancer risk assessment WO2004040298A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003282069A AU2003282069A1 (en) 2002-11-01 2003-10-31 Tumor marker proteins for diagnosis and therapy of cancer and cancer risk assessment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02090365 2002-11-01
EP02090365.4 2002-11-01

Publications (2)

Publication Number Publication Date
WO2004040298A2 WO2004040298A2 (en) 2004-05-13
WO2004040298A3 true WO2004040298A3 (en) 2005-06-09

Family

ID=32187248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/012162 WO2004040298A2 (en) 2002-11-01 2003-10-31 Tumor marker proteins for diagnosis and therapy of cancer and cancer risk assessment

Country Status (2)

Country Link
AU (1) AU2003282069A1 (en)
WO (1) WO2004040298A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050881A1 (en) * 2005-05-16 2006-11-17 Anna Favre DIAGNOSTIC KIT FOR HIRSCHSPRUNG MEGALON CONGENITAL DISEASE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001073030A2 (en) * 2000-03-28 2001-10-04 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
WO2002030973A2 (en) * 2000-10-13 2002-04-18 University Of Lausanne The caveolin-1 gene and polypeptide encoded thereby and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001073030A2 (en) * 2000-03-28 2001-10-04 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20020065396A1 (en) * 2000-03-28 2002-05-30 Fei Yang Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
WO2002030973A2 (en) * 2000-10-13 2002-04-18 University Of Lausanne The caveolin-1 gene and polypeptide encoded thereby and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ABRAHA H D ET AL: "Serum S-100 protein: A potentially useful prognostic marker in cutaneous melanoma", BRITISH JOURNAL OF DERMATOLOGY, vol. 137, no. 3, 1997, pages 381 - 385, XP002281038, ISSN: 0007-0963 *
DIFILIPPANTONIO S ET AL: "Gene expression profiles in human non-small and small-cell lung cancers", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 39, no. 13, September 2003 (2003-09-01), pages 1936 - 1947, XP004446972, ISSN: 0959-8049 *
KIM EDWARD J ET AL: "Characterization of the metastasis-associated protein, S100A4. Roles of calcium binding and dimerization in cellular localization and interaction with myosin.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 32, 8 August 2003 (2003-08-08), pages 30063 - 30073, XP002281037, ISSN: 0021-9258 *
MARENHOLZ I ET AL: "S100A16, a ubiquitously expressed EF-hand protein which is up-regulated in tumors", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 313, no. 2, 9 January 2004 (2004-01-09), pages 237 - 244, XP004480373, ISSN: 0006-291X *
PIETAS AGNIESZKA ET AL: "Molecular cloning and characterization of the human S100A14 gene encoding a novel member of the S100 family", GENOMICS, vol. 79, no. 4, April 2002 (2002-04-01), pages 513 - 522, XP002281036, ISSN: 0888-7543 *

Also Published As

Publication number Publication date
AU2003282069A1 (en) 2004-05-25
WO2004040298A2 (en) 2004-05-13
AU2003282069A8 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2003089456A3 (en) Peptide inhibitors of protein kinase c
EP1281755A3 (en) Variants of the human cyp2d6 gene
GB2321642B (en) Human telomerase reverse transcriptase promoter
Sporbert et al. Phosphorylation of vasodilator-stimulated phosphoprotein: a consequence of nitric oxide-and cGMP-mediated signal transduction in brain capillary endothelial cells and astrocytes
WO2002060955A3 (en) Modified antibodies and methods of use
BRPI0417213A (en) treatment of malignant gliomas with tgf-beta inhibitors
AU2003242305A8 (en) Hla-a24-restricted cancer antigen peptide
FR2827866B1 (en) SYNTHETIC OR NATURAL PEPTIDES BINDING PROTEIN PHOSPHATASE 2A, IDENTIFICATION METHOD AND USES
WO2003079020A3 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
WO2001055178A3 (en) Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
BR0306715A (en) Methods for diagnosis and treatment of tumors
WO2002061076A1 (en) Adiponectin-associated protein
CA2579523A1 (en) Atad3a-binding molecules for treatment, detection and prevention of cancer
WO2004040298A3 (en) Tumor marker proteins for diagnosis and therapy of cancer and cancer risk assessment
EP1536006A4 (en) Cancer antigens and utilization thereof
WO2002093174A3 (en) A method of treatment of alzheimer's disease and device therefor
WO2002018574A3 (en) Human interleukin-four induced protein
Burbaeva et al. Diversity of glutamate dehydrogenase in human brain
WO2004017992A3 (en) Ptk7 protein involvement in carcinoma
WO2005123760A3 (en) Treating cancer
ATE312179T1 (en) AGENT CONTAINING SERINE-THREONINE KINASE FOR TUMOR THERAPY AND TUMOR DIAGNOSIS
IL143862A0 (en) Human akt-3
WO2002024895A3 (en) Transcription factors and zinc finger proteins
WO2002053719A3 (en) Cytoskeleton-associated proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP